ArticleEuropean journal of organic chemistry2025
Synthetic Strategies to Access Fluorinated Azoles.
Article in European journal of organic chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- α‑Fluoronitroalkenes as Fluorinated Building Blocks: Solvent-Controlled Functionalization with Hydrazones.ACS organic & inorganic Au · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Incorporating fluorine into azoles is not only a common practice but also an essential tactic in medicinal chemistry, due to their ability to fine-tune a molecule's physicochemical, pharmacokinetic, and pharmacodynamic profiles. The strategic introduction of fluorine into nitrogen-containing five-membered heterocycles can significantly enhance metabolic stability, membrane permeability, and binding affinity-key factors in modern drug development. This review provides an up-to-date overview of key synthetic strategies for monofluorination, difluoromethylation, and trifluoromethylation across 11 prominent azoles: 1,2,3-triazoles, 1,2,4-triazoles, tetrazoles, pyrazoles, imidazoles, pyrroles, isoxazoles, oxazoles, thiazoles, thiadiazoles, and isothiazoles. This review aims to identify current limitations in the field and delineate existing research gaps that present further opportunities for innovation in these domains, which are essential for propelling pharmaceutical and biomedical research. By integrating new synthetic advancements and diverse strategies to access them, this review aims to serve as both a practical guide and a source of inspiration for chemists exploring the next generation of fluorinated azole pharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.